Oklahoma 2025 Regular Session

Oklahoma Senate Bill SB741 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	SENATE FLOOR VERSION - SB741 SFLR Page 1
4		-	(Bold face denotes Committee Amendments) 1
	3	+
	4	+	Req. No. 705 Page 1 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
	28	+	1
5	29		2
6	30		3
7	31		4
8	32		5
9	33		6
10	34		7
11	35		8
12	36		9
13	37		10
14	38		11
15	39		12
16	40		13
17	41		14
18	42		15
19	43		16
20	44		17
21	45		18
22	46		19
23	47		20
24	48		21
25	49		22
26	50		23
27	51		24
28	52
29		-	SENATE FLOOR VERSION
30		-	March 3, 2025
31		-	AS AMENDED
	53	+	STATE OF OKLAHOMA
32	54
33		-	SENATE BILL NO. 741 By: Gollihare
	55	+	1st Session of the 60th Legislature (2025)
	56	+
	57	+	SENATE BILL 741 By: Gollihare
34	58
35	59
36	60
37	61
38	62
39		-	[ practice of pharmacy - drug therapy - tests -
40		-	codification - effective date ]
	63	+	AS INTRODUCED
	64	+
	65	+	An Act relating to the practice of pharmacy; allowing
	66	+	pharmacist to test or screen for and initiate drug
	67	+	therapy for minor, nonchronic health conditions;
	68	+	specifying allowed tests; prohibiting certain test,
	69	+	screening, and treatment ; amending 59 O.S. 2021,
	70	+	Section 353.1, as amended by Section 6, Chapter 288,
	71	+	O.S.L. 2022 (59 O.S. Supp. 202 4, Section 353.1),
	72	+	which relates to definitions used in the Oklahoma
	73	+	Pharmacy Act; modifying and adding definitions;
	74	+	updating statutory language and references; providing
	75	+	for codification; and providing an effective date .
	76	+
41	77
42	78
43	79
44	80
45	81		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
46	82		SECTION 1. NEW LAW A new section of law to be codified
47	83		in the Oklahoma Statutes as Section 353.31 of Title 59, unless there
48	84		is created a duplication in numbering, reads as follows:
49	85		A. In accordance with a standing order issued by a licensed
50	86		allopathic or osteopathic physician or by the medical director of a
51	87		county or local health department, a pharmacist may test or screen
52	88		for and initiate drug therapy for minor, nonchronic health
53	89		conditions as defined in Section 353.1 of Title 59 of the Oklahoma
54	90		Statutes.
55		-	B. To test for minor, nonchronic health conditions under this
56		-	section, the pharmacist may use any test that may guide clinical
57		-	decision-making and that is:
58		-	1. Approved by, cleared by, or authorized under an emergency
59		-	use authorization by the United States Food and Drug Administration;
60		-	and
61	91
62		-	SENATE FLOOR VERSION - SB741 SFLR Page 2
63		-	(Bold face denotes Committee Amendments) 1
	92	+
	93	+	Req. No. 705 Page 2 1
	94	+	2
	95	+	3
	96	+	4
	97	+	5
	98	+	6
	99	+	7
	100	+	8
	101	+	9
	102	+	10
	103	+	11
	104	+	12
	105	+	13
	106	+	14
	107	+	15
	108	+	16
	109	+	17
	110	+	18
	111	+	19
	112	+	20
	113	+	21
	114	+	22
	115	+	23
	116	+	24
	117	+	1
64	118		2
65	119		3
66	120		4
67	121		5
68	122		6
69	123		7
70	124		8
71	125		9
72	126		10
73	127		11
74	128		12
75	129		13
76	130		14
77	131		15
78	132		16
79	133		17
80	134		18
81	135		19
82	136		20
83	137		21
84	138		22
85	139		23
86	140		24
87	141
	142	+	B. To test for minor, nonchronic health conditions under this
	143	+	section, the pharmacist may use any test that may guide clinical
	144	+	decision-making and that is:
	145	+	1. Approved by, cleared by, or authorized under an emergency
	146	+	use authorization by the United States Food and Drug Administration;
	147	+	and
88	148		2. Waived under the federal Clinica l Laboratory Improvement
89	149		Amendments of 1988 (CLIA) or deemed to be CLIA -waived for use in
90	150		patient care settings operating under a CLIA certificate.
91	151		C. A pharmacist shall not tes t or screen for streptococcus or
92	152		initiate drug therapy for streptococcus to individuals under six (6)
93	153		years of age.
94	154		SECTION 2. AMENDATORY 59 O.S. 2021, Section 353.1, as
95	155		amended by Section 6, Chapter 288, O.S.L. 2022 (59 O.S. Supp . 2024,
96	156		Section 353.1), is amended to read as follows:
97	157		Section 353.1. For the purposes of the Oklahoma Pharmacy Act:
98	158		1. “Accredited program” means those seminars, classes,
99	159		meetings, work projects, and other educational courses approved by
100	160		the Board State Board of Pharmacy for purposes of continuing
101	161		professional education;
102	162		2. “Act” means the Oklahoma Pharmacy Act;
103	163		3. “Administer” means the direct application of a drug, whether
104	164		by injection, inhalation, ingestion , or any other means, to the body
105	165		of a patient;
106		-	4. “Assistant pharmacist” means any person presently licensed
107		-	as an assistant pharmacist in the State of Oklahoma this state by
108		-	the Board pursuant to Section 353.10 of this title and for the
109		-	purposes of the Oklahoma Pharmacy Act shall be considered the same
110		-	as a pharmacist, except where otherwise specified;
111		-	5. “Board” or “State Board” means the State Board of Pharmacy;
112	166
113		-	SENATE FLOOR VERSION - SB741 SFLR Page 3
114		-	(Bold face denotes Committee Amendments) 1
	167	+
	168	+	Req. No. 705 Page 3 1
	169	+	2
	170	+	3
	171	+	4
	172	+	5
	173	+	6
	174	+	7
	175	+	8
	176	+	9
	177	+	10
	178	+	11
	179	+	12
	180	+	13
	181	+	14
	182	+	15
	183	+	16
	184	+	17
	185	+	18
	186	+	19
	187	+	20
	188	+	21
	189	+	22
	190	+	23
	191	+	24
	192	+	1
115	193		2
116	194		3
117	195		4
118	196		5
119	197		6
120	198		7
121	199		8
122	200		9
123	201		10
124	202		11
125	203		12
126	204		13
127	205		14
128	206		15
129	207		16
130	208		17
131	209		18
132	210		19
133	211		20
134	212		21
135	213		22
136	214		23
137	215		24
138	216
	217	+	4. “Assistant pharmacist ” means any person presently licensed
	218	+	as an assistant pharmacist in the State of Oklahoma this state by
	219	+	the Board pursuant to Section 353.10 of this title and for the
	220	+	purposes of the Oklahoma Pharmacy Act shall be considered t he same
	221	+	as a pharmacist, except where otherwise specified;
	222	+	5. “Board” or “State Board” means the State Board of Pharmacy;
139	223		6. “Certify” or “certification of a prescription ” means the
140	224		review of a filled prescription by a licensed pharmacist or a
141	225		licensed practitioner with dispensing authority to confirm that the
142	226		medication, labeling , and packaging of the filled prescription are
143	227		accurate and meet all requirements prescribed by state and federal
144	228		law. For the purposes of this paragraph, “licensed practitioner ”
145	229		shall not include optometrists with dispensing authority;
146	230		7. “Chemical” means any medicinal substance, whether simple or
147	231		compound or obtained through the process of the science and art of
148	232		chemistry, whether of organic or inorganic origin;
149	233		8. “Compounding” means the combining, admixing, mixing,
150	234		diluting, pooling, reconstituting , or otherwise altering of a drug
151	235		or bulk drug substance to create a drug. Compounding includes the
152	236		preparation of drugs or devices in anticipation of prescription drug
153	237		orders based on routine, regularly observed prescribing patterns;
154	238		9. “Continuing professional education ” means professional,
155	239		pharmaceutical education in the general areas of the socioeconomic
156	240		and legal aspects of health care; the properties and actions of
157		-	drugs and dosage forms ; and the etiology, characteristics , and
158		-	therapeutics of the diseased state;
159		-	10. “Dangerous drug”, “legend drug”, “prescription drug”, or
160		-	“Rx Only” means a drug:
161		-	a. for human use subject to 21 U.S.C. 353(b)(1), or
162	241
163		-	SENATE FLOOR VERSION - SB741 SFLR Page 4
164		-	(Bold face denotes Committee Amendments) 1
	242	+
	243	+	Req. No. 705 Page 4 1
	244	+	2
	245	+	3
	246	+	4
	247	+	5
	248	+	6
	249	+	7
	250	+	8
	251	+	9
	252	+	10
	253	+	11
	254	+	12
	255	+	13
	256	+	14
	257	+	15
	258	+	16
	259	+	17
	260	+	18
	261	+	19
	262	+	20
	263	+	21
	264	+	22
	265	+	23
	266	+	24
	267	+	1
165	268		2
166	269		3
167	270		4
168	271		5
169	272		6
170	273		7
171	274		8
172	275		9
173	276		10
174	277		11
175	278		12
176	279		13
177	280		14
178	281		15
179	282		16
180	283		17
181	284		18
182	285		19
183	286		20
184	287		21
185	288		22
186	289		23
187	290		24
188	291
	292	+	drugs and dosage forms; and the etiology, characteristics , and
	293	+	therapeutics of the dise ased state;
	294	+	10. “Dangerous drug”, “legend drug”, “prescription drug”, or
	295	+	“Rx Only” means a drug:
	296	+	a. for human use subject to 21 U.S.C. 353(b)(1), or
189	297		b. is labeled “Prescription Only”, or labeled with the
190	298		following statement: “Caution: Federal law restricts
191	299		this drug except for to use by or on the order of a
192	300		licensed veterinarian. ”;
193	301		11. “Director” means the Executive Director of the State Board
194	302		of Pharmacy unless context clearl y indicates otherwise;
195	303		12. “Dispense” or “dispensing” means the interpretatio n,
196	304		evaluation, and implementation of a prescription drug order
197	305		including the preparation and delivery of a drug or device to a
198	306		patient or a patient ’s agent in a suitable containe r appropriately
199	307		labeled for subsequent administration to, or use by, a patient.
200	308		Dispense includes sell, distribute, leave with, give away, dispose
201	309		of, deliver, or supply;
202	310		13. “Dispenser” means a retail pharmacy, hospital pharmacy, a
203	311		group of chain pharma cies under common ownership and control that do
204	312		not act as a wholesale distrib utor, or any other person authorized
205	313		by law to dispense or administer prescription drugs, and the
206	314		affiliated warehouses or distributions of such entities under common
207	315		ownership and control that do not act as a wholesale distributor.
208		-	For the purposes of this paragraph, “dispenser” dispenser does not
209		-	mean a person who dispenses only products to be used in animals in
210		-	accordance with 21 U.S.C. 360b(a)(5);
211		-	14. “Distribute” or “distribution” means the sale, purchase,
212		-	trade, delivery, handling, storage, or receipt of a product, and
213	316
214		-	SENATE FLOOR VERSION - SB741 SFLR Page 5
215		-	(Bold face denotes Committee Amendments) 1
	317	+
	318	+	Req. No. 705 Page 5 1
	319	+	2
	320	+	3
	321	+	4
	322	+	5
	323	+	6
	324	+	7
	325	+	8
	326	+	9
	327	+	10
	328	+	11
	329	+	12
	330	+	13
	331	+	14
	332	+	15
	333	+	16
	334	+	17
	335	+	18
	336	+	19
	337	+	20
	338	+	21
	339	+	22
	340	+	23
	341	+	24
	342	+	1
216	343		2
217	344		3
218	345		4
219	346		5
220	347		6
221	348		7
222	349		8
223	350		9
224	351		10
225	352		11
226	353		12
227	354		13
228	355		14
229	356		15
230	357		16
231	358		17
232	359		18
233	360		19
234	361		20
235	362		21
236	363		22
237	364		23
238	365		24
239	366
	367	+	For the purposes of this paragraph, “dispenser” dispenser does not
	368	+	mean a person who dispenses only products to be used in animals in
	369	+	accordance with 21 U.S.C. 360b(a)(5);
	370	+	14. “Distribute” or “distribution” means the sale, purchase,
	371	+	trade, delivery, handling, storage, or recei pt of a product, and
240	372		does not include the dispensing of a product pursuant to a
241	373		prescription executed in accordance with 21 U.S.C. 353(b)(1) or the
242	374		dispensing of a product approv ed under 21 U.S.C. 360b(b); provided,
243	375		taking actual physical possession of a product or title shall not be
244	376		required;
245	377		15. “Doctor of Pharmacy” means a person licensed by the Board
246	378		to engage in the practice of pharmacy. The terms “pharmacist”,
247	379		“D.Ph.”, and “Doctor of Pharmacy” shall be interchangeable and shall
248	380		have the same meaning wherever they appear in the Oklahoma Statutes
249	381		and the rules promulgated by the Board;
250	382		16. “Drug outlet” means all manufacturers, repackagers,
251	383		outsourcing facilities, wholesale distributors, third-party
252	384		logistics providers, pharmacies, and all other facilities which are
253	385		engaged in dispensing, delivery, distribution , or storage of
254	386		dangerous drugs;
255	387		17. “Drugs” means all medicinal substances and preparations
256	388		recognized by the Unite d States Pharmacopoeia Pharmacopeia and
257	389		National Formulary, or any revision th ereof, and all substances and
258	390		preparations intended for external and/or internal use in the cure,
259		-	diagnosis, mitigation, treatment , or prevention of disease in humans
260		-	or animals and all subst ances and preparations, other than food,
261		-	intended to affect the structure or any function of the body of a
262		-	human or animals;
263	391
264		-	SENATE FLOOR VERSION - SB741 SFLR Page 6
265		-	(Bold face denotes Committee Amendments) 1
	392	+
	393	+	Req. No. 705 Page 6 1
	394	+	2
	395	+	3
	396	+	4
	397	+	5
	398	+	6
	399	+	7
	400	+	8
	401	+	9
	402	+	10
	403	+	11
	404	+	12
	405	+	13
	406	+	14
	407	+	15
	408	+	16
	409	+	17
	410	+	18
	411	+	19
	412	+	20
	413	+	21
	414	+	22
	415	+	23
	416	+	24
	417	+	1
266	418		2
267	419		3
268	420		4
269	421		5
270	422		6
271	423		7
272	424		8
273	425		9
274	426		10
275	427		11
276	428		12
277	429		13
278	430		14
279	431		15
280	432		16
281	433		17
282	434		18
283	435		19
284	436		20
285	437		21
286	438		22
287	439		23
288	440		24
289	441
	442	+	diagnosis, mitigation, treatment , or prevention of disease in humans
	443	+	or animals and all substances and preparations, other than food,
	444	+	intended to affect the structure or any function of the body of a
	445	+	human or animals;
290	446		18. “Drug sample” means a unit of a prescription drug packaged
291	447		under the authority and responsibility of the manufact urer that is
292	448		not intended to be sold and is intended to promote the sale of th e
293	449		drug;
294	450		19. “Durable medical equipment ” has the same meaning as
295	451		provided by Section 2 of this act 375.2 of this title;
296	452		20. “Filled prescription” means a packaged prescription
297	453		medication to which a label has been affixed which contains such
298	454		information as is required by the Oklahoma Pharmacy Act;
299	455		21. “Hospital” means any institution licensed as a hospital by
300	456		this state for the care and treatment of patients, or a pharmacy
301	457		operated by the Oklahoma Department of Veterans Affairs;
302	458		22. “Licensed practitioner ” means an allopathic physician,
303	459		osteopathic physician, podiatric physician, dentist, veterinarian ,
304	460		or optometrist licensed to practice and authorized to prescribe
305	461		dangerous drugs within the scope of practice of such practitioner;
306	462		23. “Manufacturer” or “virtual manufacturer ” means with respect
307	463		to a product:
308	464		a. a person that holds an application approved under 21
309	465		U.S.C. 355 or a license issued under 42 U.S.C. 262 for
310		-	such product, or if such p roduct is not the subject of
311		-	an approved application or license, the person who
312		-	manufactured the product,
313	466
314		-	SENATE FLOOR VERSION - SB741 SFLR Page 7
315		-	(Bold face denotes Committee Amendments) 1
	467	+
	468	+	Req. No. 705 Page 7 1
	469	+	2
	470	+	3
	471	+	4
	472	+	5
	473	+	6
	474	+	7
	475	+	8
	476	+	9
	477	+	10
	478	+	11
	479	+	12
	480	+	13
	481	+	14
	482	+	15
	483	+	16
	484	+	17
	485	+	18
	486	+	19
	487	+	20
	488	+	21
	489	+	22
	490	+	23
	491	+	24
	492	+	1
316	493		2
317	494		3
318	495		4
319	496		5
320	497		6
321	498		7
322	499		8
323	500		9
324	501		10
325	502		11
326	503		12
327	504		13
328	505		14
329	506		15
330	507		16
331	508		17
332	509		18
333	510		19
334	511		20
335	512		21
336	513		22
337	514		23
338	515		24
339	516
	517	+	such product, or if such product is not the subject of
	518	+	an approved application or license, the person who
	519	+	manufactured the product,
340	520		b. a co-licensed partner of the person described in
341	521		subparagraph a of this paragraph that obtains the
342	522		product directly from a person desc ribed in this
343	523		subparagraph or subparagraph a of this paragraph,
344	524		c. an affiliate of a person described in subparagraph a
345	525		or b of this paragraph who receives the product
346	526		directly from a person described in this subparagraph
347	527		or in subparagraph a or b of this paragraph, or
348	528		d. a person who contracts with another to manufacture a
349	529		product;
350	530		24. “Manufacturing” means the production, preparation,
351	531		propagation, compounding, conversion , or processing of a device or a
352	532		drug, either directly or indirectly by extraction fr om substances of
353	533		natural origin or independently by means of chemical or biological
354	534		synthesis and includes any packaging or repackaging of the
355	535		substances or labeling or relabeling of its container, and the
356	536		promotion and marketing of such drugs or devices. The term
357	537		“manufacturing” manufacturing also includes the preparation and
358	538		promotion of commercially available products from bulk compounds for
359	539		resale by licensed pharmacies, licensed practitioners , or other
360	540		persons;
361		-	25. “Medical gas” means those gases including those in liquid
362		-	state upon which the manufacturer or distributor has placed one of
363		-	several cautions, such as “Rx Only”, in compliance with federal law;
364	541
365		-	SENATE FLOOR VERSION - SB741 SFLR Page 8
366		-	(Bold face denotes Committee Amendments) 1
	542	+
	543	+	Req. No. 705 Page 8 1
	544	+	2
	545	+	3
	546	+	4
	547	+	5
	548	+	6
	549	+	7
	550	+	8
	551	+	9
	552	+	10
	553	+	11
	554	+	12
	555	+	13
	556	+	14
	557	+	15
	558	+	16
	559	+	17
	560	+	18
	561	+	19
	562	+	20
	563	+	21
	564	+	22
	565	+	23
	566	+	24
	567	+	1
367	568		2
368	569		3
369	570		4
370	571		5
371	572		6
372	573		7
373	574		8
374	575		9
375	576		10
376	577		11
377	578		12
378	579		13
379	580		14
380	581		15
381	582		16
382	583		17
383	584		18
384	585		19
385	586		20
386	587		21
387	588		22
388	589		23
389	590		24
390	591
	592	+	25. “Medical gas” means those gases inc luding those in liquid
	593	+	state upon which the manufacturer or distributor has placed one of
	594	+	several cautions, such as “Rx Only”, in compliance with federal law;
391	595		26. “Medical gas order” means an order for medical gas issued
392	596		by a licensed prescriber;
393	597		27. “Medical gas distributor ” means a person licensed to
394	598		distribute, transfer, wholes ale, deliver, or sell medical gases on
395	599		drug orders to suppliers or other entities licensed to use,
396	600		administer, or distribute medical gas and may also include a patient
397	601		or ultimate user;
398	602		28. “Medical gas supplier ” means a person who dispenses medical
399	603		gases on drug orders only to a patient or ultimate user;
400	604		29. “Medicine” means any drug or combination of drugs which has
401	605		the property of curing, preventing, treating, diagnosing , or
402	606		mitigating diseases, or which is used for that purpose;
403	607		30. “Minor, nonchronic health condition” means a typically
404	608		short-term health condition that is generally managed with
405	609		noncontrolled drug therapies, minimal treatment, or self -care, and
406	610		is limited to the following:
407	611		a. influenzas,
408	612		b. streptococcus,
409	613		c. SARS-CoV-2,
410	614		d. lice, and
411		-	e. other emerging and existing public health threats
412		-	identified by the State Commissioner of Health if
413		-	permitted by an order, rule, or regulation;
414	615
415		-	SENATE FLOOR VERSION - SB741 SFLR Page 9
416		-	(Bold face denotes Committee Amendments) 1
	616	+
	617	+	Req. No. 705 Page 9 1
	618	+	2
	619	+	3
	620	+	4
	621	+	5
	622	+	6
	623	+	7
	624	+	8
	625	+	9
	626	+	10
	627	+	11
	628	+	12
	629	+	13
	630	+	14
	631	+	15
	632	+	16
	633	+	17
	634	+	18
	635	+	19
	636	+	20
	637	+	21
	638	+	22
	639	+	23
	640	+	24
	641	+	1
417	642		2
418	643		3
419	644		4
420	645		5
421	646		6
422	647		7
423	648		8
424	649		9
425	650		10
426	651		11
427	652		12
428	653		13
429	654		14
430	655		15
431	656		16
432	657		17
433	658		18
434	659		19
435	660		20
436	661		21
437	662		22
438	663		23
439	664		24
440	665
	666	+	e. other emerging and existing public health threats
	667	+	identified by the State Commissioner of Health if
	668	+	permitted by an order, rule, or regulation;
441	669		31. “Nonprescription drugs ” means medicines or drugs which are
442	670		sold without a prescription and which are prepa ckaged for use by the
443	671		consumer and labeled in accordance with the requirements of the
444	672		statutes and regulations of this state and the federal government.
445	673		Such items shall also in clude medical and dental supplies and
446	674		bottled or nonbulk chemicals which are sold or offered for sale to
447	675		the general public if such articles or preparations meet the
448	676		requirements of the Federal Food, Drug , and Cosmetic Act, 21
449	677		U.S.C.A., Section 321 et seq. ;
450	678		31. 32. “Outsourcing facility ” including “virtual outsourcing
451	679		facility” means a facility at one geographic location or address
452	680		that:
453	681		a. is engaged in the compounding of sterile drugs,
454	682		b. has elected to register as an outsourcing facility,
455	683		and
456	684		c. complies with all requirements of 21 U.S.C. 353b;
457	685		32. 33. “Package” means the smallest individual saleable unit
458	686		of product for distribution by a manufacturer or repackager that is
459	687		intended by the manufacturer for ultimate sale to the dispenser of
460	688		such product. For the purposes of this paragraph, “individual
461	689		saleable unit” means the smallest container of a product introduced
462		-	into commerce by the manufacturer or repackager that is intend ed by
463		-	the manufacturer or repackager for individual sale to a dispenser;
464	690
465		-	SENATE FLOOR VERSION - SB741 SFLR Page 10
466		-	(Bold face denotes Committee Amendments) 1
	691	+
	692	+	Req. No. 705 Page 10 1
	693	+	2
	694	+	3
	695	+	4
	696	+	5
	697	+	6
	698	+	7
	699	+	8
	700	+	9
	701	+	10
	702	+	11
	703	+	12
	704	+	13
	705	+	14
	706	+	15
	707	+	16
	708	+	17
	709	+	18
	710	+	19
	711	+	20
	712	+	21
	713	+	22
	714	+	23
	715	+	24
	716	+	1
467	717		2
468	718		3
469	719		4
470	720		5
471	721		6
472	722		7
473	723		8
474	724		9
475	725		10
476	726		11
477	727		12
478	728		13
479	729		14
480	730		15
481	731		16
482	732		17
483	733		18
484	734		19
485	735		20
486	736		21
487	737		22
488	738		23
489	739		24
490	740
	741	+	into commerce by the manufacturer or repackager that is intended by
	742	+	the manufacturer or repackager for individual sale to a dispenser;
491	743		33. 34. “Person” means an individual, partnership, limited
492	744		liability company, corporation , or association, unless the context
493	745		otherwise requires;
494	746		34. 35. “Pharmacist-in-charge” or “PIC” means the pharmacist
495	747		licensed in this state responsible for the managemen t control of a
496	748		pharmacy and all other aspects of the practice of pharmacy in a
497	749		licensed pharmacy as defined by Section 353.18 of this title;
498	750		35. 36. “Pharmacy” means a place regularly licensed by the
499	751		State Board of Pharmacy in which prescriptions, drugs, medicines,
500	752		chemicals, and poisons are compounded or dispensed or such place
501	753		where pharmacists practice the profession of pharmacy, or a pharmacy
502	754		operated by the Oklahoma Department of Veterans Affairs;
503	755		36. 37. “Pharmacy technician”, “technician”, “Rx tech”, or
504	756		“tech” means a person issued a Technician technician permit by the
505	757		State Board of Pharmacy to assist the pharmacist and perform
506	758		nonjudgmental, technical, manipulative, non -discretionary functions
507	759		in the prescription department under the immediate and direct
508	760		supervision of a pharmacist;
509	761		37. 38. “Poison” means any substance which when introduced into
510	762		the body, either directly or by absorption, produces violent,
511	763		morbid, or fatal changes, or which destroys living tissue with which
512	764		such substance comes in to contact;
513		-	38. 39. “Practice of pharmacy ” means:
514	765
515		-	SENATE FLOOR VERSION - SB741 SFLR Page 11
516		-	(Bold face denotes Committee Amendments) 1
	766	+
	767	+	Req. No. 705 Page 11 1
	768	+	2
	769	+	3
	770	+	4
	771	+	5
	772	+	6
	773	+	7
	774	+	8
	775	+	9
	776	+	10
	777	+	11
	778	+	12
	779	+	13
	780	+	14
	781	+	15
	782	+	16
	783	+	17
	784	+	18
	785	+	19
	786	+	20
	787	+	21
	788	+	22
	789	+	23
	790	+	24
	791	+	1
517	792		2
518	793		3
519	794		4
520	795		5
521	796		6
522	797		7
523	798		8
524	799		9
525	800		10
526	801		11
527	802		12
528	803		13
529	804		14
530	805		15
531	806		16
532	807		17
533	808		18
534	809		19
535	810		20
536	811		21
537	812		22
538	813		23
539	814		24
540	815
	816	+	38. 39. “Practice of pharmacy ” means:
541	817		a. the interpretation and e valuation of prescription
542	818		orders,
543	819		b. the compounding, dispensing, administering , and
544	820		labeling of drugs and devices, except labeling by a
545	821		manufacturer, repackager , or distributor of
546	822		nonprescription drugs and commercially packaged legend
547	823		drugs and devices,
548	824		c. the participation in drug selection and drug
549	825		utilization reviews,
550	826		d. the proper and safe storage of drugs and devices and
551	827		the maintenance of proper records thereof,
552	828		e. the responsibility for advising by counseling and
553	829		providing information, where profess ionally necessary
554	830		or where regulated, of therapeutic values, content,
555	831		hazards, and use of drugs and devices,
556	832		f. the offering or performing of those acts, services,
557	833		operations, or transactions necessary in the conduct,
558	834		operation, management , and control of a pharmacy, or
559	835		g. the ordering, performing, and interpreting of tests
560	836		for minor, nonchronic health conditions that meet the
561	837		requirements of Section 1 of this act and the
562	838		initiation of drug therapy for minor, nonchronic
563	839		health conditions, or
564	840
565		-	SENATE FLOOR VERSION - SB741 SFLR Page 12
566		-	(Bold face denotes Committee Amendments) 1
	841	+
	842	+	Req. No. 705 Page 12 1
	843	+	2
	844	+	3
	845	+	4
	846	+	5
	847	+	6
	848	+	7
	849	+	8
	850	+	9
	851	+	10
	852	+	11
	853	+	12
	854	+	13
	855	+	14
	856	+	15
	857	+	16
	858	+	17
	859	+	18
	860	+	19
	861	+	20
	862	+	21
	863	+	22
	864	+	23
	865	+	24
	866	+	1
567	867		2
568	868		3
569	869		4
570	870		5
571	871		6
572	872		7
573	873		8
574	874		9
575	875		10
576	876		11
577	877		12
578	878		13
579	879		14
580	880		15
581	881		16
582	882		17
583	883		18
584	884		19
585	885		20
586	886		21
587	887		22
588	888		23
589	889		24
590	890
591	891		h. the provision of those acts or services that are
592	892		necessary to provide pharmaceutical care;
593	893		39. 40. “Preparation” means an article which may or may not
594	894		contain sterile products compounded in a licensed pharmacy pursuant
595	895		to the order of a licensed prescriber;
596	896		40. 41. “Prescriber” means a person licensed in this state who
597	897		is authorized to prescribe dangerous drugs within the scope of
598	898		practice of the person ’s profession;
599	899		41. 42. “Prescription” means and includes any order for drug or
600	900		medical supplies written or signed, or transmitted by word of mouth,
601	901		telephone, or other means of communication:
602	902		a. by a licensed prescriber,
603	903		b. under the supervision of an Oklahoma licensed
604	904		practitioner, an Oklaho ma licensed advanced practice
605	905		registered nurse Advanced Practice Registered Nurse,
606	906		or an Oklahoma licensed physician assistant, or
607	907		c. by an Oklahoma licensed wholesaler or distributor as
608	908		authorized in Section 353.29.1 of this title;
609	909		42. 43. “Product” means a prescription drug in a finished
610	910		dosage form for administration to a patien t without substantial
611	911		further manufacturing, such as capsules, tablets, and lyophilized
612	912		products before reconstitution. “Product” Product does not include
613	913		blood components inten ded for transfusion, radioactive drugs or
614	914		biologics and medical gas;
615	915
616		-	SENATE FLOOR VERSION - SB741 SFLR Page 13
617		-	(Bold face denotes Committee Amendments) 1
	916	+
	917	+	Req. No. 705 Page 13 1
	918	+	2
	919	+	3
	920	+	4
	921	+	5
	922	+	6
	923	+	7
	924	+	8
	925	+	9
	926	+	10
	927	+	11
	928	+	12
	929	+	13
	930	+	14
	931	+	15
	932	+	16
	933	+	17
	934	+	18
	935	+	19
	936	+	20
	937	+	21
	938	+	22
	939	+	23
	940	+	24
	941	+	1
618	942		2
619	943		3
620	944		4
621	945		5
622	946		6
623	947		7
624	948		8
625	949		9
626	950		10
627	951		11
628	952		12
629	953		13
630	954		14
631	955		15
632	956		16
633	957		17
634	958		18
635	959		19
636	960		20
637	961		21
638	962		22
639	963		23
640	964		24
641	965
642	966		43. 44. “Repackager”, including “virtual repackager”, means a
643	967		person who owns or operates an establishment that repacks and
644	968		relabels a product or package for further sale or distribution
645	969		without further transaction;
646	970		44. 45. “Sterile drug” means a drug that is int ended for
647	971		parenteral administration, an ophthalmic or oral inhalation drug in
648	972		aqueous format, or a drug that is required to be sterile under state
649	973		and federal law;
650	974		45. 46. “Supervising physician” means an individual holding a
651	975		current license to practice as a physician from the State Board of
652	976		Medical Licensure and Supervision, pursuant to the provisions of the
653	977		Oklahoma Allopathic Medical and Surgical Licensure and Supervision
654	978		Act, or the State Board of Osteopathic Examiners, pursuant to the
655	979		provisions of the Oklahoma Osteopathic Medicine Act, who supervises
656	980		an advanced practice registered nurse Advanced Practice Registered
657	981		Nurse as defined in Section 567.3a of this title, and who i s not in
658	982		training as an intern, resident, or fellow. To be eligible to
659	983		supervise an advanced practice registered nurse Advanced Practice
660	984		Registered Nurse, such physician shall remain in compliance with the
661	985		rules promulgated by the State Board of Medical L icensure and
662	986		Supervision or the State Board of Osteopathic Examiners;
663	987		46. 47. “Supportive personnel ” means technicians and auxiliary
664	988		supportive persons who are regularly paid employees of a pharmacy
665	989
666		-	SENATE FLOOR VERSION - SB741 SFLR Page 14
667		-	(Bold face denotes Committee Amendments) 1
	990	+
	991	+	Req. No. 705 Page 14 1
	992	+	2
	993	+	3
	994	+	4
	995	+	5
	996	+	6
	997	+	7
	998	+	8
	999	+	9
	1000	+	10
	1001	+	11
	1002	+	12
	1003	+	13
	1004	+	14
	1005	+	15
	1006	+	16
	1007	+	17
	1008	+	18
	1009	+	19
	1010	+	20
	1011	+	21
	1012	+	22
	1013	+	23
	1014	+	24
	1015	+	1
668	1016		2
669	1017		3
670	1018		4
671	1019		5
672	1020		6
673	1021		7
674	1022		8
675	1023		9
676	1024		10
677	1025		11
678	1026		12
679	1027		13
680	1028		14
681	1029		15
682	1030		16
683	1031		17
684	1032		18
685	1033		19
686	1034		20
687	1035		21
688	1036		22
689	1037		23
690	1038		24
691	1039
692	1040		who work and perform tasks in the pharmacy as authorized by Section
693	1041		353.18A of this title;
694	1042		47. 48. “Third-party logistics provider ” including “virtual
695	1043		third-party logistics provider ” means an entity that provides or
696	1044		coordinates warehousing, or other logistics services of a product in
697	1045		interstate commerce on beh alf of a manufacturer, wholesale
698	1046		distributor, or dispenser of a product but do es not take ownership
699	1047		of the product, nor have responsibility to direct the sale or
700	1048		disposition of the product. For the purposes of this paragraph,
701	1049		“third-party logistics provid er” third-party logistics provider does
702	1050		not include shippers and the United States Postal Service;
703	1051		48. 49. “Wholesale distributor ” including “virtual wholesale
704	1052		distributor” means a person other than a manufacturer, a
705	1053		manufacturer’s co-licensed partner, a third-party logistics
706	1054		provider, or repackager engaged in wholesale distributio n as defined
707	1055		by 21 U.S.C. 353(e)(4) as amended by the Drug Supply Chain Security
708	1056		Act;
709	1057		49. 50. “County jail” means a facility operated by a county for
710	1058		the physical detention and correction of persons charged with, or
711	1059		convicted of, criminal offenses or ordinance violations or persons
712	1060		found guilty of civil or criminal contempt;
713	1061		50. 51. “State correctional facility ” means a facility or
714	1062		institution that houses a prisoner population u nder the jurisdiction
715	1063		of the Department of Corrections;
716	1064
717		-	SENATE FLOOR VERSION - SB741 SFLR Page 15
718		-	(Bold face denotes Committee Amendments) 1
	1065	+
	1066	+	Req. No. 705 Page 15 1
	1067	+	2
	1068	+	3
	1069	+	4
	1070	+	5
	1071	+	6
	1072	+	7
	1073	+	8
	1074	+	9
	1075	+	10
	1076	+	11
	1077	+	12
	1078	+	13
	1079	+	14
	1080	+	15
	1081	+	16
	1082	+	17
	1083	+	18
	1084	+	19
	1085	+	20
	1086	+	21
	1087	+	22
	1088	+	23
	1089	+	24
	1090	+	1
719	1091		2
720	1092		3
721	1093		4
722	1094		5
723	1095		6
724	1096		7
725	1097		8
726	1098		9
727	1099		10
728	1100		11
729	1101		12
730	1102		13
731	1103		14
732	1104		15
733	1105		16
734	1106		17
735	1107		18
736	1108		19
737	1109		20
738	1110		21
739	1111		22
740	1112		23
741	1113		24
742	1114
743	1115		51. 52. “Unit dose package” means a package that contains a
744	1116		single dose drug with the name, strength, control number, and
745	1117		expiration date of that drug on the label; and
746	1118		52. 53. “Unit of issue packag e” means a package that provides
747	1119		multiple doses of the same drug, but each drug is individually
748	1120		separated and includes the name, lot number, and expiration date.
749	1121		SECTION 3. This act shall become effective November 1, 2025.
750		-	~~COMMITTEE REPORT BY: COMMITTE E ON HEALTH AND HUMAN SERVICES~~
751		-	~~March 3,~~ 2025 ~~- DO PASS AS AMENDED~~
	1122	+
	1123	+	60-1-705 DC 1/15/2025 1:15:47 PM